Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial to Evaluate Safety and Tolerability of Cannabidiol (Kanbis®) for the Treatment of Parkinson's Disease Symptoms

NCT06629389 is registered in ClinicalTrials.gov with Laboratorio Elea Phoenix S.A. as lead sponsor.

NCT NCT06629389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06629389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial to Evaluate Safety and Tolerability of Cannabidiol (Kanbis®) for the Treatment of Parkinson's Disease Symptoms
Lead sponsor
Laboratorio Elea Phoenix S.A.
Phase
Phase 2
Overall status
Recruiting
Start date
November 28, 2024
Completion date
November 30, 2026
Enrollment
88 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease